PlasmaGen Biosciences Secures Rs 150 Crore in Funding to Expand Operations

Bengaluru-based biopharma company PlasmaGen Biosciences has successfully raised Rs 150 crore, with ViNS Bioproducts leading the investment along with contributions from high-net-worth individuals, family offices, pharma entrepreneurs, and existing investors. This startup, which is supported by Eight Road Ventures, attained this funding at a valuation exceeding Rs 1,500 crore.

PLasmaGen has accumulated more than Rs 600 crore in funding to date from notable investors including Fidelity’s FIL Capital Investments, Eight Roads Ventures, and F-Prime Capital. The funds will primarily be allocated to enhance international operations, diversify the product portfolio, and fortify manufacturing and leadership capabilities, as stated in a press release from PlasmaGen Biosciences.

About PlasmaGen Biosciences

Founded in 2010, PlasmaGen Biosciences concentrates on the production and marketing of plasma-derived therapies such as immunoglobulin, albumin, and clotting factors. The company aims to address the demand-supply gap for these essential medicines in India. It operates a modern fractionation plant located in Kolar, Karnataka, targeting sectors like neurology, hematology, and critical care, with an objective of achieving self-sufficiency in plasma products.

International Expansion Plans

According to PlasmaGen, the company has identified distribution partners in crucial export markets and is currently working on securing regulatory approvals to commence international sales. India continues to be a significant market for the firm, which is broadening its services across hospitals and physicians via a cold-chain-supported distribution network.

PlasmaGen reports that it initiated commercial operations in 2024 at its plasma fractionation facility in Kolar, situated near Bengaluru. The company claims this facility is among only five such establishments in India and proudly asserts itself as the first pure-play plasma biopharma entity. Since the launch of operations at Kolar, PlasmaGen has experienced robust revenue growth and is now gearing up to penetrate overseas markets.